Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Bone health in HIV-infected children, adolescents and young adults: a systematic review.

Arpadi SM, Shiau S, Marx-Arpadi C, Yin MT.

J AIDS Clin Res. 2014 Nov;5(11). pii: 374. Epub 2014 Nov 9.

2.

Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T; AIDS Clinical Trials Group A5303 Study Team.

Clin Infect Dis. 2015 Oct 1;61(7):1179-88. doi: 10.1093/cid/civ455. Epub 2015 Jun 9.

3.

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.

Ustianowski A, Arends JE.

Infect Dis Ther. 2015 Jun;4(2):145-57. doi: 10.1007/s40121-015-0070-1. Epub 2015 Jun 2.

4.

Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients.

Grant PM, Sheikh V, DerSimonian R, Rupert A, Roby G, Pau A, Sneller MC, Rico SV, Brown TT, Sereti I.

AIDS Res Hum Retroviruses. 2015 Jul;31(7):739-44. doi: 10.1089/AID.2015.0028. Epub 2015 May 21.

5.

Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.

Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT.

HIV Clin Trials. 2015 Mar-Apr;16(2):66-71. doi: 10.1179/1528433614Z.0000000010. Epub 2015 Apr 15.

6.

Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Lo Re V 3rd, Lynn K, Stumm ER, Long J, Nezamzadeh MS, Baker JF, Hoofnagle AN, Kapalko AJ, Mounzer K, Zemel BS, Tebas P, Kostman JR, Leonard MB.

J Infect Dis. 2015 Sep 15;212(6):924-33. doi: 10.1093/infdis/jiv147. Epub 2015 Mar 9.

7.

Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study.

Pfefferbaum A, Rogosa DA, Rosenbloom MJ, Chu W, Sassoon SA, Kemper CA, Deresinski S, Rohlfing T, Zahr NM, Sullivan EV.

Neurobiol Aging. 2014 Jul;35(7):1755-68. doi: 10.1016/j.neurobiolaging.2014.01.008. Epub 2014 Jan 13.

8.

The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.

Weitzmann MN.

Scientifica (Cairo). 2013;2013:125705. doi: 10.1155/2013/125705. Epub 2013 Feb 3. Review.

9.

Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.

Huang JS, Hughes MD, Riddler SA, Haubrich RH; Aids Clinical Trials Group A5142 Study Team.

HIV Clin Trials. 2013 Sep-Oct;14(5):224-34. doi: 10.1310/hct1405-224.

10.
11.

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.

Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso W, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second Line study team.

AIDS. 2013 Sep 24;27(15):2403-11. doi: 10.1097/01.aids.0000432534.47217.b4.

12.

Bone mineral density in children and adolescents with perinatal HIV infection.

DiMeglio LA, Wang J, Siberry GK, Miller TL, Geffner ME, Hazra R, Borkowsky W, Chen JS, Dooley L, Patel K, van Dyke RB, Fielding RA, Gurmu Y, Jacobson DL; Pediatric HIVAIDS Cohort Study (PHACS).

AIDS. 2013 Jan 14;27(2):211-20. doi: 10.1097/QAD.0b013e32835a9b80.

13.

The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity.

Klassen K, Martineau AR, Wilkinson RJ, Cooke G, Courtney AP, Hickson M.

PLoS One. 2012;7(9):e44845. doi: 10.1371/journal.pone.0044845. Epub 2012 Sep 12.

14.

Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy.

Puthanakit T, Saksawad R, Bunupuradah T, Wittawatmongkol O, Chuanjaroen T, Ubolyam S, Chaiwatanarat T, Nakavachara P, Maleesatharn A, Chokephaibulkit K.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):477-83. doi: 10.1097/QAI.0b013e31826ea89b.

15.

Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: women's interagency HIV study.

Sharma A, Tian F, Yin MT, Keller MJ, Cohen M, Tien PC.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):469-76. doi: 10.1097/QAI.0b013e31826cba6c.

16.

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.

Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Østergaard L, Langdahl BL, Laursen AL.

PLoS One. 2012;7(3):e32445. doi: 10.1371/journal.pone.0032445. Epub 2012 Mar 29.

17.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, Quiros-Roldan E, Brianese N, Cesana BM, Re MC, Torti C.

BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38.

18.

Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial.

Arpadi SM, McMahon DJ, Abrams EJ, Bamji M, Purswani M, Engelson ES, Horlick M, Shane E.

Am J Clin Nutr. 2012 Mar;95(3):678-85. doi: 10.3945/ajcn.111.024786. Epub 2012 Jan 18.

19.

Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.

Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE.

HIV AIDS (Auckl). 2011;3:53-9. doi: 10.2147/HIV.S15588. Epub 2011 Jun 28.

20.

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.

Brown TT, Ross AC, Storer N, Labbato D, McComsey GA.

Antivir Ther. 2011;16(7):1063-72. doi: 10.3851/IMP1874.

Items per page

Supplemental Content

Write to the Help Desk